Accepted Manuscript

PCSK9 inhibition for patients with and without prior coronary revascularization: Potential additional benefit of a novel therapeutic agent

Eliano P. Navarese, Paolo Raggi

PII: S0021-9150(18)31248-6

DOI: 10.1016/j.atherosclerosis.2018.07.038

Reference: ATH 15645

To appear in: Atherosclerosis

Received Date: 23 July 2018

Accepted Date: 26 July 2018

Please cite this article as: Navarese EP, Raggi P, PCSK9 inhibition for patients with and without prior coronary revascularization: Potential additional benefit of a novel therapeutic agent, *Atherosclerosis* (2018), doi: 10.1016/j.atherosclerosis.2018.07.038.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

PCSK9 inhibition for patients with and without prior coronary revascularization: Potential additional benefit of a novel therapeutic agent

^{1,2,3,4} Eliano P Navarese, ^{4,5}Paolo Raggi

¹ INOVA Heart and Vascular Institute, Fairfax, VA, USA; ² Interventional Cardiology and Cardiovascular Research, Cardiovascular Research Center, Mater Dei Hospital, Bari, Italy and ³ SIRIO MEDICINE network; ⁴Mazankowski Alberta Heart Institute, ⁵Department of Medicine, University of Alberta, Edmonton, Canada.

Correspondence to

Paolo Raggi: Mazankowski Alberta Heart Institute, 8440 112 Street, 5A9-014, Edmonton, AB T6G 2B7, Canada. E-mail: raggi@ualberta.ca

Keywords: PCSK9, lipid lowering, lipoproteins, low density lipoprotein cholesterol

Download English Version:

https://daneshyari.com/en/article/11030696

Download Persian Version:

https://daneshyari.com/article/11030696

<u>Daneshyari.com</u>